Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Uncategorized

    The Janus Corner

    wadmin1By wadmin1March 12, 2016Updated:August 12, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    I.E.Cock1,2*
    1School of Natural Sciences, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, Australia.
    2Environmental Futures Centre, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, Australia.

    Pharmacognosy Communications,2016,6,3,255-258.
    Published: April 2021
    Type: The Janus Corner

    ABSTRACT
    Recent studies have reported that extracts prepared from the medicinal plants Cistus incanus and Pelargonium sidoides prevent HIV from binding to human cells, thereby preventing it from those infecting cells.1,2 The extracts were reported to inhibit a wide range of HIV-1 and HIV-2 clinical isolates, including a viral isolate which is resistant to all other drugs which are generally used as a part of normal anti-retroviral combinational therapies. The phytochemical extract compounds were found to target and bind to viral envelope proteins. The active compounds bind the cellular proteins and prevent them from interacting with host cell surface CD4 receptors. Of further interest, the research team also reported that the extracts not only blocked HIV cell entry, but had similar effects against both Ebola and Marburg viruses. The team speculated that the extracts may also have similar preventative effects against a wider range of enveloped viruses, included influenza viruses and therefore have broad medical implications. Notably, the study also trialled the extracts in long term studies to determine whether prolonged treatment would result in the development of viral resistance and reported no resistant viruses were found. The research has exciting implications. As the extracts have very different antiviral activities to all current clinical therapies, the extracts may be useful complementary therapies for the prevention and treatment of a wide range of viral diseases.Read more. . .
    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up